194 related articles for article (PubMed ID: 21084997)
1. Risk factors influencing antibody responses to Kaposi's sarcoma-associated herpesvirus latent and lytic antigens in patients under antiretroviral therapy.
Guadalupe M; Pollock BH; Westbrook S; Redding S; Bullock D; Anstead G; Agan BK; Marconi VC; Barbieri S; Sankar V; Rebeles J; Flahive Y; Schoolfield J; Wang L; Lei X; Dow D; Yeh CK; Dang H; Infante AJ; Gao SJ
J Acquir Immune Defic Syndr; 2011 Jan; 56(1):83-90. PubMed ID: 21084997
[TBL] [Abstract][Full Text] [Related]
2. Seroreactivity to Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) latent nuclear antigen in AIDS-associated Kaposi's sarcoma patients depends on CD4+ T-cell count.
de Souza VA; Pierrotti LC; Sumita LM; Freire WS; Segurado AA; Pannuti CS
J Med Virol; 2007 Oct; 79(10):1562-8. PubMed ID: 17705173
[TBL] [Abstract][Full Text] [Related]
3. A prospective study of Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus in adults with human immunodeficiency virus-1.
Newton R; Carpenter L; Casabonne D; Beral V; Babiker A; Darbyshire J; Weller I; Weiss R; Kwan A; Bourboulia D; Munoz F; Lagos D; Boshoff C
Br J Cancer; 2006 May; 94(10):1504-9. PubMed ID: 16705315
[TBL] [Abstract][Full Text] [Related]
4. Kaposi sarcoma herpes virus antibody response and viremia following highly active antiretroviral therapy in the Swiss HIV Cohort study.
Sullivan SG; Hirsch HH; Franceschi S; Steffen I; Amari EB; Mueller NJ; Magouras I; Biggar RJ; Rickenbach M; Clifford GM;
AIDS; 2010 Sep; 24(14):2245-52. PubMed ID: 20543658
[TBL] [Abstract][Full Text] [Related]
5. Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.
Bihl F; Mosam A; Henry LN; Chisholm JV; Dollard S; Gumbi P; Cassol E; Page T; Mueller N; Kiepiela P; Martin JN; Coovadia HM; Scadden DT; Brander C
AIDS; 2007 Jun; 21(10):1245-52. PubMed ID: 17545700
[TBL] [Abstract][Full Text] [Related]
6. Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma.
Renwick N; Halaby T; Weverling GJ; Dukers NH; Simpson GR; Coutinho RA; Lange JM; Schulz TF; Goudsmit J
AIDS; 1998 Dec; 12(18):2481-8. PubMed ID: 9875587
[TBL] [Abstract][Full Text] [Related]
7. Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-Infected patients receiving highly active antiretroviral therapy.
Wilkinson J; Cope A; Gill J; Bourboulia D; Hayes P; Imami N; Kubo T; Marcelin A; Calvez V; Weiss R; Gazzard B; Boshoff C; Gotch F
J Virol; 2002 Mar; 76(6):2634-40. PubMed ID: 11861829
[TBL] [Abstract][Full Text] [Related]
8. Detection and quantification of Kaposi's sarcoma-associated herpesvirus to predict AIDS-associated Kaposi's sarcoma.
Engels EA; Biggar RJ; Marshall VA; Walters MA; Gamache CJ; Whitby D; Goedert JJ
AIDS; 2003 Aug; 17(12):1847-51. PubMed ID: 12891072
[TBL] [Abstract][Full Text] [Related]
9. Viral load of human herpesvirus 8 in peripheral blood of human immunodeficiency virus-infected patients with Kaposi's sarcoma.
Tedeschi R; Enbom M; Bidoli E; Linde A; De Paoli P; Dillner J
J Clin Microbiol; 2001 Dec; 39(12):4269-73. PubMed ID: 11724831
[TBL] [Abstract][Full Text] [Related]
10. Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome.
Cattelan AM; Calabrò ML; Gasperini P; Aversa SM; Zanchetta M; Meneghetti F; De Rossi A; Chieco-Bianchi L
J Natl Cancer Inst Monogr; 2001; (28):44-9. PubMed ID: 11158206
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal analysis of the humoral response to Kaposi's sarcoma-associated herpesvirus after primary infection in children.
Olp LN; Minhas V; Gondwe C; Poppe LK; Rogers AM; Kankasa C; West JT; Wood C
J Med Virol; 2016 Nov; 88(11):1973-81. PubMed ID: 27062052
[TBL] [Abstract][Full Text] [Related]
12. Identification, expression, and immunogenicity of Kaposi's sarcoma-associated herpesvirus-encoded small viral capsid antigen.
Lin SF; Sun R; Heston L; Gradoville L; Shedd D; Haglund K; Rigsby M; Miller G
J Virol; 1997 Apr; 71(4):3069-76. PubMed ID: 9060668
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology of Kaposi's sarcoma-associated herpesvirus in HIV-1-infected US persons in the era of combination antiretroviral therapy.
Labo N; Miley W; Benson CA; Campbell TB; Whitby D
AIDS; 2015 Jun; 29(10):1217-25. PubMed ID: 26035321
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen.
Simpson GR; Schulz TF; Whitby D; Cook PM; Boshoff C; Rainbow L; Howard MR; Gao SJ; Bohenzky RA; Simmonds P; Lee C; de Ruiter A; Hatzakis A; Tedder RS; Weller IV; Weiss RA; Moore PS
Lancet; 1996 Oct; 348(9035):1133-8. PubMed ID: 8888167
[TBL] [Abstract][Full Text] [Related]
15. Trends in Kaposi's sarcoma-associated Herpesvirus antibodies prior to the development of HIV-associated Kaposi's sarcoma: a nested case-control study.
Wakeham K; Johnston WT; Nalwoga A; Webb EL; Mayanja BN; Miley W; Elliott AM; Whitby D; Newton R
Int J Cancer; 2015 Jun; 136(12):2822-30. PubMed ID: 25395177
[TBL] [Abstract][Full Text] [Related]
16. Comparison of human sera reactivities in immunoblots with recombinant human herpesvirus (HHV)-8 proteins associated with the latent (ORF73) and lytic (ORFs 65, K8.1A, and K8.1B) replicative cycles and in immunofluorescence assays with HHV-8-infected BCBL-1 cells.
Zhu L; Wang R; Sweat A; Goldstein E; Horvat R; Chandran B
Virology; 1999 Apr; 256(2):381-92. PubMed ID: 10191203
[TBL] [Abstract][Full Text] [Related]
17. Kaposi's sarcoma-associated herpesvirus seroprevalence in selected german patients: evaluation by different test systems.
Preiser W; Szép NI; Lang D; Doerr HW; Rabenau HF
Med Microbiol Immunol; 2001 Dec; 190(3):121-7. PubMed ID: 11827200
[TBL] [Abstract][Full Text] [Related]
18. Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma.
Gao SJ; Kingsley L; Hoover DR; Spira TJ; Rinaldo CR; Saah A; Phair J; Detels R; Parry P; Chang Y; Moore PS
N Engl J Med; 1996 Jul; 335(4):233-41. PubMed ID: 8657239
[TBL] [Abstract][Full Text] [Related]
19. Kaposi's sarcoma-associated herpesvirus seropositivity is associated with type 2 diabetes mellitus: A case-control study in Xinjiang, China.
Cui M; Fang Q; Zheng J; Shu Z; Chen Y; Fan Y; Zhao J; Wood C; Zhang T; Zeng Y
Int J Infect Dis; 2019 Mar; 80():73-79. PubMed ID: 30639407
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of Kaposi's sarcoma-associated herpesvirus serological assays using clinically and serologically defined reference standards and latent class analysis.
Nascimento MC; de Souza VA; Sumita LM; Freire W; Munoz F; Kim J; Pannuti CS; Mayaud P
J Clin Microbiol; 2007 Mar; 45(3):715-20. PubMed ID: 17182752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
